Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy of KT-253, a Targeted Protein Degrader of MDM2, in Patients with Relapsed/Refractory (R/R) Solid Tumors, Lymphoma, High Grade Myeloid Malignancies and Acute Lymphoblastic Leukemia (ALL)

Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy of KT-253, a Targeted Protein Degrader of MDM2, in Patients with Relapsed/Refractory (R/R) Solid Tumors, Lymphoma, High Grade Myeloid Malignancies and Acute Lymphoblastic Leukemia (ALL)

American Society of Clinical Oncology (ASCO) 2024

Muhammad R. Khawaja, Abdul Rafeh Naqash, Reva Schneider, Aditi Shastri, Maximilian Stahl, Justin C. Moser, Nagla Abdel Karim, Yazan Madanat, Brian Jonas, Eytan Stein, Shirish Gadgeel, James McCloskey, Ashwin Gollerkeri, Rachelle Perea, Yogesh Chutake, Sagar Agarwal, Patrick Henrick, Naval Daver